IVERMECTIN in Peru – documentary
August 14, 2020
TrialSite News productions introduces a new documentary special about Peru, COVID-19, and the acceptance of Ivermectin as a formally approved treatment for the novel coronavirus. Filmed right in Peru by a Peruvian film crew contracted by TrialSite, the documentary was commissioned to help other parts of the world better understand why Peru and the surrounding region have become an epicenter for a community physician movement that advocated for the off-label use of Ivermectin to treat COVID-19 patients. Link to Video
Ivermectin Breaking into American News as Doctors Come Forward
Dr. Lauren Mickey, an ears, eyes and throat specialist at Glenwood Medical Mall in West Monroe, Louisiana, was recently interviewed by local television station Fox 14, reporting that the cheap and widely available medication Ivermectin is being used at this provider’s practice—successfully treating COVID-19 patients, reports the news station.
Ivermectin Study Reveals Fantastic Results: 100% of 60 Patients Better in an Average of Just Under 6 Days
Ivermectin Use In the Dominican Republic Review by Dr. Mobeen Sayed
The Rescue Group (Grupo Rescue) is a leading national private health network in the Caribbean nation of Dominican Republic. They have treated 1,300 early stage COVID-19. Patients and have observed dramatic results.
Favipiravir – Developed by the Dept. of Defense
As we recently reported, here and here, Favipiravir is an up-and-coming COVID-19 treatment around the world. Given over $200 million has been spent by the U.S. Department of Defense on this drug, it is oddly lacking in approval and current research by the U.S. The Austin Journal of Public Health Epidemiology looked into the drug in the June article “Favipiravir and USA.” They note that it “was invented as the most useful drug for bioengineered pandemics.” And while first developed in Japan, it has garnered lots of interest from the Department of Defense. U.S. trials started in 2014 and completed in 2015, but there has been no FDA approval or market authorization. AJPHE’s author sought the answer and, “wrote to FDA twice, only to know that it is not possible to know anything because of federal confidentiality (personal communication).”
IVERMECTIN
